Table 1.
Selected clinical and laboratory variables of total group (n = 47) before (T0) and 1 month after (T1) radioiodine treatment provided as median (range)
| Variables (RI + units) | T0 | T1 | Median of difference between T1 and T0 (range) | P |
|---|---|---|---|---|
| Age (years) | 13 (7–16) | |||
| BW (kg) | 3.8 (1.5‐6.5) | 4.2 (2.0‐6.4) | 0.2 (−0.3 to 1.1) | <.001 |
| BCS | 4/9 (2‐8 /9) | 5/9 (2–8 /9) | 0 (−1 to 2) | <.001 |
| MCS | Normal; n = 7 (15%) | Normal; n = 22 (47%) | Improved | <.001 |
| Mild loss; n = 20 (43%) | Mild loss; n = 18 (38%) | |||
| Moderate loss; n = 15 (32%) | Moderate loss; n = 6 (13%) | |||
| Severe loss; n = 5 (10%) | Severe loss; n = 1 (2%) | |||
| BP (mm Hg) | 160 (125‐225) | 165 (125‐220) | 0 (−70 to 50) | .67 |
| Serum TT4 (0.8‐4.7 μg/dL) | 8.3 (2.2‐>13) | 0.9 (<0.7‐8) | −6.7 (<−12.3 to −0.6) | <.001 |
| Serum TSH (<0.3 ng/mL) | <0.03 (<0.03‐0.04) | 0.09 (<0.03‐0.95) | −0.05 (0 to 0.92) | <.001 |
| Serum creatinine (0.9‐2.3 mg/dL) | 0.67 (0.39‐1.55) | 1.23 (0.39‐2) | 0.52 (−0.57 to 1.17) | <.001 |
| Serum urea (16‐38 mg/dL) | 22.7 (12.6‐53.5) | 28.0 (17.4‐58.8) | 4.2 (−6.2 to 20) | <.001 |
| Serum SDMA (0‐14 μg/dL) | 10 (1‐18) | 11 (6‐20) | 0.0 (−7 to 19) | .61 |
| USG | >1.050 (1.016‐>1.050) | 1.042 (1.013‐>1.050) | −0.008 (−0.037 to 0.010) | <.001 |
| UPC (<0.33) | 0.5 (0.2‐2.4) | 0.2 (0.1‐0.82) | −0.3 (−2.1 to 0.12) | <.001 |
Abbreviations: BCS, body condition score; BP, blood pressure; BW, body weight; MCS, muscle condition score; RI, reference interval; SDMA, symmetric dimethylarginine; TSH, serum thyroid‐stimulating hormone; TT4, serum total thyroxine; UPC, urinary protein : creatinine ratio; USG, urine specific gravity.